Cambridge MA 02138,USA
+1 877-267-2685
info@summatherapeutics.com

About

Summa’s founders and leaders have deep understanding of the management of vascular disease derived from years of hands-on patient care experience. That experience informs Summa’s approach to ergonomic medical device design. Summa has two issued patents, pending patent applications, and FDA 510(k) clearance for marketing in the U.S.

LEADERSHIP

Timothy P. Murphy, M.D. spent 25 years as an Interventional Radiologist and clinical trialist achieving the rank of Full Professor, Research Track, at Alpert School of Medicine at Brown University. He is a Past President of the Society of lnterventional Radiology (SIR) and recipient of the Charles T. Dotter Award in 2018. He served in leadership roles of three NIH-sponsored vascular disease clinical trials (CORAL, CLEVER, and ATTRACT), and has published over 200 journal articles and given more than 185 presentations all over the world. Dr. Murphy joined Summa full time in 2018.

In his more than 25 years training fellows at Brown University Dr. Murphy would impress on trainees the importance of eliminating unnecessary steps. That informs his approach to medical device design. Dr. Murphy believes that ergonomic medical device design is crucial for enhancing user experience, reducing strain, and improving efficiency and patient outcomes. Summa Therapeutics is a commercial-stage company currently field testing its FDA-cleared novel injectable angioplasty balloon catheter, and evaluating its ability to simplify complex peripheral revascularization procedures among patients at risk for amputation due to arterial insufficiency.

Curriculum Vitae

Carmen D. Pagán Meléndez is a highly experienced Quality and Compliance Professional with over twenty-six years of expertise in the Medical Device and Combination Product Industries. She has held various roles, including Consultant, Quality Engineer, Auditor, Production Planner, Manager, and Director at companies such as Boston Scientific, Maquet, and Guidant. Carmen has a proven track record in assessing, implementing, and improving quality systems, along with extensive experience in working with regulations and managing audits. Carmen is bilingual in English and Spanish and holds a B.S. in Industrial Engineering (Magna Cum Laude) from the University of Puerto Rico, Mayagüez campus. She also holds certifications as an ASQ Certified Medical Device Auditor #634 and Exemplar Global Principal Quality Management System Auditor #113778 (Scope: ISO13485:2016).

Throughout her career, Carmen has demonstrated a wide range of competencies, including Quality Systems Assessments/Audits, Training, Supplier Audits, Risk Management, Quality Systems Implementation and Improvement, Interim Quality Management, FDA Inspection Preparation, Coaching & Management, FDA/Notified Body Remediation, and Independent Reviewer for various processes. Her professional experience includes roles such as Quality & Compliance Consultant, Quality Director, Quality and Compliance Manager, Manufacturing Manager, Compliance Coordinator, and Process Characterization Engineer. Carmen has also been involved in developing and improving compliant and sustainable Quality Management Systems, performing Quality Systems Audits following various regulations and standards, managing FDA inspections and Notified Body Assessments, and supporting various quality system remediation projects.

AdvisorS

 

Dr. Ansel is an internationally renowned interventional expert, both in peripheral vascular and cardiovascular procedures.  He serves as an invited faculty member at many of the largest cardiovascular conferences and medical meetings all over the world. 

Dr. Ansel currently serves as System Medical Chief, Vascular Program – OhioHealth and is the Associate Medical Director of the OhioHealth Research and Innovation Institute in Columbus, Ohio. He is an Assistant Clinical Professor of Medicine in the Department of Internal Medicine at the University of Toledo Medical Center, Toledo, Ohio. 

Dr. Ansel has served as a primary investigator for numerous national and international research trials helping to develop improved patient care to those suffering with peripheral and cardiovascular disease. Dr. Ansel is a founding board member of the Vascular InterVentional Advances Conference (VIVA) which is a non-profit organization dedicated to the education and research of vascular disease. 

Dr. Ansel received his medical degree from The Ohio State University College of Medicine where he also completed a postgraduate research fellowship in cardiology. He completed his residency and internship at the University of Toledo and received his post-fellowship training in peripheral vascular intervention at the Ochsner Clinic in New Orleans.

Dr. Ansel is affiliated with OhioHealth Heart and Vascular Physicians in Columbus, Ohio.  He is a former member of the Peripheral Vascular Committee for the American College of Cardiology and continues to serve as a member of several professional societies. Dr. Ansel has served on the editorial board for Catheter and Cardiovascular Intervention, Cardiovascular Revascularization Medicine, Annals of Vascular Surgery, and Endovascular Today.  He has contributed to journals such as The New England Journal of Medicine, Circulation, Journal of Endovascular Therapy, and The American Journal of Cardiology and has authored many medical book chapters. 

James F. Benenati, M.D., FSIR, is a practicing Interventional Radiologist, Medical Director, Noninvasive Vascular Laboratory and Fellowship Program Director at the Miami Cardiac & Vascular Institute at Baptist Hospital in Miami, Florida.

He is a Clinical Professor of Radiology at Florida International University College of Medicine and Collaborative Professor of Radiology at the University of South Florida College of Medicine.  He is past President of SIR.  He served as President of the Vascular Division for the Intersocietal Accreditation Committee (IAC) and served for over a decade on their board.  He served as the annual meeting chairman for SIR in 2005.  He was the recipient of the SIR Charles T. Dotter Award in 2014.

He has participated in numerous clinical research projects and national trials.  His interest include peripheral arterial disease, abdominal aortic aneurysm and management of pulmonary embolism. He has authored and co-authored more than 100 scientific publications.  He has been a Program Director of ISET for over 20 years.

He attended the University of Notre Dame as an undergraduate, received his medical degree from the University of South Florida College of Medicine, completed a residency in Diagnostic Radiology at Indiana University and a fellowship at Johns Hopkins.

Kevin Herman, M.D., is an accomplished interventional radiologist with a wealth of experience and achievements in the field. He is a Partner at Advanced Vascular & Interventional Services, LLP, and is associated with several medical centers and hospitals, such as the Interventional Institute at Holy Name Medical Center and St. Mary’s General Hospital. His academic contributions include serving as an Adjunct Clinical Assistant Professor at Touro College of Osteopathic Medicine. Dr. Herman has been an active member of professional societies, such as the Society of Interventional Radiology, and serves as committee member as part of the Critical Limb Ischemia Global Society.  He has received numerous awards and honors.  He has also been involved in extensive clinical research, with a focus on topics such as arterial and venous interventions, and has been a prolific author of publications, abstracts, and presentations in the field of interventional radiology. His professional activities also include serving on various committees and as a reviewer for the Journal of Vascular and Interventional Radiology. Dr. Herman’s clinical expertise and contributions have significantly advanced the field of interventional radiology.

Robert A. Lookstein, MD MHCDL FSIR FAHA FSVM is Professor of Radiology and Surgery at the Icahn School of Medicine at Mount Sinai (ISMMS). After attending medical school at the State University of NY (SUNY) Health Science Center at Brooklyn in 1995, he completed his radiology residency and fellowship in Vascular and Interventional Radiology at ISMMS in New York. He subsequently joined the Division of Vascular and Interventional Radiology as Faculty in 2002.

Dr. Lookstein currently lectures around the world on various subjects in the field of Vascular and Interventional Radiology including peripheral arterial imaging and intervention, endovascular interventions, aortic stent-grafts, and deep vein thrombosis. He is recognized as an innovator in the field of peripheral vascular disease and noninvasive vascular imaging. His clinical practice is focused on the diagnosis and treatment of peripheral vascular disease.

Dr. Lookstein currently serves as Executive Vice Chairman in The Department of Diagnostic, Molecular, and Interventional Radiology for the Mount Sinai Health System. He previously served as System Vice Chair for Interventional Services as well as Division Chief of Vascular and Interventional Radiology.

Dr. Lookstein is currently involved in numerous research studies related to peripheral vascular disease including the VENITI VICI venous stent trial, the SAVAL study evaluating drug coated stents in the lower leg arteries, the PRESERVE

registry evaluating the safety and efficacy of Inferior Vena Cava filters, as well as the NHLBI funded BEST-CLI evaluating the role of endovascular revascularization for critical limb ischemia.Dr. Lookstein has authored hundreds of scientific abstracts and manuscripts related to cardiovascular imaging and intervention and has served as Assistant Editor for the American Journal of Roentgenology.

He is a regular faculty member of numerous national and international meetings including The International Society of Endovascular Therapy, Advanced Interventional Management, The Society of Interventional Radiology Annual Scientific Meeting, The Radiologic Society of North America, and The American Heart Association Scientific Sessions, and Vascular Interventional Advances (VIVA).

He is the Course Program Director of several national education courses including Lower Extremity Arterial Revascularization (LEARN), TransRadial EndovAscular Therapy (TREAT), Transcatheter Cardiovascular Therapeutics (TCT), and LINC Mount Sinai.

Dr. Lookstein serves on numerous committees within the Mount Sinai Health System related to patient safety and quality, novel procedure oversight, cardiovascular disease intervention value analysis, and performance improvement.

Rahul S. Patel, MD FSIR is Assistant Professor of Radiology and Surgery at the Icahn School of Medicine at Mount Sinai (ISMMS). After attending medical at the University of Miami in 2002, he completed his residency in Diagnostic Radiology at Jackson Memorial Hospital in Miami, Florida. He then finished his fellowship in Vascular and Interventional Radiology at the Baptist and Cardiovascular Institute also in Miami, Florida in 2008. He joined the division of Vascular and Interventional Radiology at ISSM in 2012 after spending time as faculty at University of Maryland School of Medicine.

Dr. Patel is currently involved in numerous research studies related to peripheral vascular disease, interventional oncology, portal hypertension and complex porto-mesenteric thrombosis, and bariatric embolization.

Dr. Patel has published over 170 scientific abstracts and manuscripts related to cardiovascular imaging, peripheral vascular disease, interventional oncology, portal hypertension, and peripheral embolization.

He is a regular faulty member of numerous national meetings including the International Society of Endovascular Therapy, Advanced Interventional Management, The Society of Interventional Radiology Annual Scientific Meeting, The Radiologic Society of North America, and The American Heart Association Scientific Sessions, Transcatheter Cardiovascular Therapeutics (TCT), LINC Mount Sinai, and Vascular Interventional Advances (VIVA). He is also the course program director for TransRadial EndoVascular Therapy (TREAT).

Dr. Rosenfield is an interventional cardiologist and vascular specialist performing complex cardiac and vascular interventions. He is Section Head for Vascular Medicine and Intervention in the Division of Cardiology at Massachusetts General Hospital. He earned a masters degree in Health Care Delivery Science from Dartmouth College.  

In addition to being a master clinician and interventionalist, Dr. Rosenfield has dedicated much of his career to educating fellows, residents, students, and colleagues.  He is the recipient of the distinguished Laennec award for his outstanding teaching and mentorship. 

He is also a researcher and clinical trialist.  He designed and served as national principle investigator for several landmark studies, including Aspire 2, Levant 2, Superb, ACT 1, and NIH BEST-CLI trial. 

He is a leader in the cardiovascular world, having been elected to the Board of Governors of American College of Cardiology, immediate past-President of the MA ACC Chapter, and immediate past-President of the Society for Cardiovascular Angiography and Interventions (SCAI).  Dr. Rosenfield is a founding member of VIVA, a 501c3 organization, and sits on its board of directors.

At Massachusetts General Hospital, he is the Medical director of the PERT Program, which he founded with his colleagues; he also founded the National PERT Consortium, a 501c3 organization dedicated to improving management, outcomes, and awareness of Pulmonary Embolism, and he served as its initial President; he remains a member of the PERT Consortium Executive Committee.

John H. Rundback, MD, is a renowned interventional radiologist in practice since 1993 and is the Director of the Interventional Institute at Holy Name Medical Center. He is board-certified in radiology and holds a Certificate of Added Qualification in Angiography and Interventional Radiology. He has been named as a Top Doctor by Castle Connolly.

Dr. Rundback’s research interests include peripheral arterial, carotid and aortic aneurysmal disease, deep venous thrombosis and varicose veins, as well as state-of-the art minimally invasive cancer therapies, and he is the principal investigator on a number of multi-center trials. He has presented at more than 200 conferences, and is the program chairman for his own peripheral arterial disease symposium. He has served as an editor and reviewer for peer-reviewed medical journals, and published over 100 articles.

Dr. Rundback is a past member of the Board of Directors of the Society of Interventional Radiology Foundation and Founding Chair for the Foundation’s Cooperative Alliance for Interventional Research Clinical Trials Network. At Holy Name, he serves on the Patient Safety Committee, the Cancer Committee and the Credentialing Committee.

Dr. Rundback earned his medical degree from SUNY Downstate Medical Center, after which he completed his internship at St. Vincent’s Hospital and Medical Center, New York, N.Y. He completed his diagnostic radiology residency at Beth Israel Medical Center, New York, N.Y., where he also served as chief resident, and completed his fellowship in interventional radiology at Washington Hospital Center, Washington, D.C.